News

This 28-year-old woman presented with a large hyperpigmented patch on the right side of her upper back. Although the lesion developed over the past 2 years, it has been "sinking in" over the past 2 weeks. The patient denies any trauma, pain, discomfort, or pruritis, as well as any family history of cancers, lymphoma, or autoimmune disease. However, she has a history of gastroesophageal reflux disease and onychomycosis, and her grandfather has a similar lesion.

While rhabdomyolysis has been recognized as a consequence of crush injuries since the late 1800s, the most significant step toward finding the condition's causes, mechanisms, and management strategies occurred when physicians who treated crush injuries from the 1941 London Blitz identified a link between rhabdomyolysis and renal impairment.

Combining results from studies involving nearly 12,000 rheumatoid arthritis patients finds the fusion protein etanercept less likely than other TNF inhibitors to be discontinued due to infections.

(EULAR 2014) New research finds erectile dysfunction common among gout patients, and distinctive differences between men and women in predisposing factors and treatment risks.

(EULAR 2014) The first international guidelines on the treatment of polymyalgia rheumatica have been finalized and presented at the European rheumatologists conference this week in Paris. Publication is forthcoming.

New from Europe: Two questionnaires to help you and your patients assess the impact of psoriatic arthritis on their lives. Both are available online, in English, for free.

Although the primary outcomes of the US National Institutes of Health Women's Health Initiative trial suggested daily calcium plus vitamin D supplementation significantly reduced hip fracture in postmenopausal women, a follow-up investigation found no difference in hip fracture incidence between the study's supplement and placebo groups nearly 5 years after the intervention phase ended.

When does gout need treatment? A new set of staging criteria hopes to clarify the answer, and a separate report warns of the risks of unjustified treatment.

For antiphospholipid syndrome, some alternatives to vitamin K antagonists including rituximab and hydroxychloroquine may be suitable, says an international task force. Two clinical trials are recruiting to provide better information.